Substance / Medication

Olodaterol

SNOMED 704459002 UMLS C2934193

Overview

Active Ingredient

olodaterol

RxNorm CUI

1546059

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Chronic bronchitis

Pulmonary emphysema

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

18 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis

NCT00132938Phase 4Completed5660 enrolled

Inhaled Steroid Reduces Systemic Inflammation in COPD

NCT00175565Phase 4Completed50 enrolled

Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

NCT00181207Phase 4Completed50 enrolled

COPD on Primary Care Treatment (COOPT)

NCT00184977Phase 4Completed270 enrolled

Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD

NCT00538148Phase 4Completed668 enrolled

View all 18 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Effect of fixed-dose tiotropium/olodaterol combined therapy on exercise-related outcome measures in individuals with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Alsubheen Sanaa A, Rodrigues Myanca, Thorlund Kristian · Expert Rev Respir Med · 2025

PMID: 40530954Meta-Analysis

Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination.

Rogliani Paola, Ritondo Beatrice Ludovica, Zerillo Bartolomeo et al. · COPD · 2020

PMID: 32252547Meta-Analysis

Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.

Miravitlles Marc, Urrutia Gerard, Mathioudakis Alexander G et al. · Respir Res · 2017

PMID: 29178871Meta-AnalysisFull text (PMC)

The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis.

Lee Hyun Woo, Kim Hyung-Jun, Lee Chang-Hoon · Br J Clin Pharmacol · 2017

PMID: 27957746Meta-AnalysisFull text (PMC)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.

Roskell Neil S, Anzueto Antonio, Hamilton Alan et al. · Int J Chron Obstruct Pulmon Dis · 2014

PMID: 25114521Meta-AnalysisFull text (PMC)

A randomized, crossover, placebo controlled, double-blind trial of the effects of tiotropium-olodaterol on neuromuscular performance during exercise in COPD.

Cao Min, Calmelat Robert A, Kierstead Peter et al. · J Appl Physiol (1985) · 2022

PMID: 35323052RCTFull text (PMC)

Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADOTrials.

Rabe Klaus F, Chalmers James D, Miravitlles Marc et al. · Adv Ther · 2021

PMID: 33175291RCTFull text (PMC)

Effects of lung deflation induced by tiotropium/olodaterol on the cardiocirculatory responses to exertion in COPD.

Berton Danilo C, Marques Renata D, Palmer Brandon et al. · Respir Med · 2019

PMID: 31522031RCT

[The efficacy and safety of tiotropium/olodaterol fixed-dose combination in Chinese patients with chronic obstructive pulmonary disease: a pooled subgroup analysis of TONADO 1+2].

Bai C X, Tang Y, Xin J B et al. · Zhonghua Jie He He Hu Xi Za Zhi · 2019

PMID: 31694094RCT

The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).

Beeh Kai-Michael, Derom Eric, Echave-Sustaeta José et al. · Int J Chron Obstruct Pulmon Dis · 2016

PMID: 26893551RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Olodaterol (substance)
SNOMED CT: 704459002
UMLS CUI: C2934193
RxNorm CUI: 1546059

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.